2014
DOI: 10.1507/endocrj.ej13-0460
|View full text |Cite
|
Sign up to set email alerts
|

Colestimide improves glycemic control <i>via</i> hepatic glucose production in <i>db/db</i> mice

Abstract: The objective of this study was to assess the chronic effects of a bile acid sequestrant, colestimide, on glucose metabolism. After db/db mice were fed a diet containing colestimide or cholic acid (CA) for 12 weeks, we investigated the impact of these agents on glucose and lipid metabolism. Colestimide significantly reduced the elevated fasting blood glucose level (p<0.01), and CA even more markedly reduced fasting blood glucose. The blood glucose level after an oral glucose load was significantly lower in the… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
4
0

Year Published

2018
2018
2020
2020

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(4 citation statements)
references
References 37 publications
0
4
0
Order By: Relevance
“…Several studies show that BA depletion influences glucose homeostasis by BA sequestration (BAS) or abrogation of enzymes responsible for BA production, such as Cyp7a1 and Cyp8b1 as follows. BAS ameliorates glucose homeostasis in ob/ob mice [23], db/db mice [24], fatty liver Shionogi mice [25], and also in humans [26]. Those observations suggest that depletion of BAs from intestinal luminal contents improves glucose homeostasis in both humans and mice.…”
Section: Discussionmentioning
confidence: 80%
“…Several studies show that BA depletion influences glucose homeostasis by BA sequestration (BAS) or abrogation of enzymes responsible for BA production, such as Cyp7a1 and Cyp8b1 as follows. BAS ameliorates glucose homeostasis in ob/ob mice [23], db/db mice [24], fatty liver Shionogi mice [25], and also in humans [26]. Those observations suggest that depletion of BAs from intestinal luminal contents improves glucose homeostasis in both humans and mice.…”
Section: Discussionmentioning
confidence: 80%
“…Similarly, Watanabe et al (50) and Yamakawa et al (52) recently reported that colestimide, another BAS, improved glycemic control and suggested this effect is driven by hepatic changes. In this study, hepatic SREBP2 (Srebf2) mRNA levels were found to be increased with colestimide treatments by PCR; however, in our study, we failed to find a significant increase in Srebf2 mRNA levels in mice treated with colesevelam, despite evidence that other SREBP2 transcriptional target genes (e.g., Hmgcr) were significantly increased with BAS (colesevelam) treatments (50,52). Here, we present evidence that colesevelam lowered plasma glucose levels and increased glycolysis in ZDF rats.…”
Section: ' 3'utr 1459 a U U G A C A C C U G C A C U G U G C C A U U | | | | | | | Hsa-mir-183-5p U C A C U U A A G A U G G U C A C G G U mentioning
confidence: 86%
“…Nevertheless, the molecular mechanisms by which colesevelam improves glucose metabolism remain unclear. Both human studies and studies in diabetic rodent models suggest that colesevelam likely mediates its metabolic effects, in part, through the liver (6,32,38,41,52). Thus the goal of this study was to investigate whether a hepatic mechanism contributes to colesevelam's glucose-lowering capacity.…”
Section: Discussionmentioning
confidence: 99%
“…Recent studies suggest that decreased functional SCD promotes lipid oxidation over storage, decreased lipogenesis, increased beta-oxidation, and increased glucose utilization [ 36 ]. In this sense, during the follow-up on our participants, the DNAm of SCD correlated with glycemic metabolism parameters (glucose, insulin levels, and HOMA-IR) [ 37 ] and adherence to the MedDiet.…”
Section: Discussionmentioning
confidence: 99%